Advances in the function of solute carrier family 7 and its correlation with tumors

doi:10.3877/cma.j.issn.2095-1221.2024.01.006

Abstract

Abstract:

Solute carrier family 7 (SLC7) consisted of 14 members, is divided into two subfamilies: cationic amino acid transporters (CAT) and L-type amino acid transporters (LAT) . These transporters are widely expressed in cells and tissues. They play a crucial role in the transportation of various amino acids, thereby exerting significant physiological importance. In recent years, it has been found that the members of SLC7 family play an important role in the occurrence and development of diseases. This review mainly introduces and analyzes the characteristics of each member of SLC7 family, reviews the research progress of their involvement in the occurrence and development of tumors, and introduces their application prospect in tumor precision therapy.

Key words: Solute carrier family 7, Amino acid transporters, Neoplasms

Ying Wang, Hu Zhao, Qingson Sheng. Advances in the function of solute carrier family 7 and its correlation with tumors[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(01): 37-44.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2024.01.006

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2024/V14/I01/37

Figures/Tables 5

References 59

1	Jin J, Kim C, Xia Q, et al. Activation of mTORC1 at late endosomes misdirects T cell fate decision in older individuals[J]. Sci Immunol. 2021, 6(60):eabg0791.
2	Cormerais Y, Massard PA, Vucetic M, et al. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)[J]. J Biol Chem, 2018, 293:2877-2887.
3	Polewski MD, Reveron-Thornton RF, Cherryholmes GA, et al. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties[J]. Stem Cells Dev, 2017, 26:1236-1246.
4	Robert SM, Buckingham SC, Campbell SL, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma[J]. Sci Transl Med, 2015, 7(289):289ra86.
5	Jungnickel KEJ, Parker JL, Newstead S. Structural basis for amino acid transport by the CAT family of SLC7 transporters[J]. Nat Commun, 2018, 9(1):550.
6	Jäger K, Bönisch U, Risch M,et al.Detection and Regulation of Cationic Amino Acid Transporters in Healthy and Diseased Ocular Surface[J]. Invest Ophthalmol Vis Sci,2009,50(3):1112-1121.
7	You S, Zhu X, Yang Y, et al.SLC7A1 overexpression is involved in energy metabolism reprogramming to induce tumor progression in epithelial ovarian cancer and is associated with immune-infiltrating cells[J]. J Oncol, 2022,2022:5864826.
8	Missiaen R, Anderson NM, Kim LC, et al. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment[J]. Cell Metab, 2022, 34(8):1151-1167.e7.
9	Toral M, Jimenez R, Montoro-Molina S, et al.Thyroid hormones stimulate L-arginine transport in human endothelial cells[J]. J Endocrinol, 2018, 239(1):49-62.
10	Sala R, Rotoli BM, Colla E, et al. Two-way arginine transport in human endothelial cells: TNF-α stimulation is restricted to system y(+)[J]. Am J Physiol Cell Physiol, 2002, 282(1):C134-C143.
11	He W, Zhang J, Liu B, et al. S119N mutation of the E3 ubiquitin ligase SPOP suppresses SLC7A1 degradation to regulate hepatoblastoma progression[J]. Mol Ther Oncolytics, 2020, 19:149-162.
12	Zhai X, Chen X, Wan Z, et al. Identification of the novel therapeutic targets and biomarkers associated of prostate cancer with cancer-associated fibroblasts (CAFs)[J]. Front Oncol, 2023, 13:1136835.
13	Closs EI, Gräf P, Habermeier A, et al. Human cationic amino acid transporters hCAT-1, hCAT-2A, andhCAT-2B: three related carriers with distinct transport properties[J]. Biochemistry, 1997, 36(21):6462-6468.
14	Jiang S, Zou J, Dong J, et al. Lower SLC7A2 expression is associated with enhanced multidrug resistance, less immune infiltrates and worse prognosis of NSCLC[J]. Cell Commun Signal, 2023, 21(1):9.
15	Rothenberg ME, Doepker MP, Lewkowich IP, et al. Cationic amino acid transporter 2 regulates inflammatory homeostasis in the lung[J]. Proc Natl Acad Sci U S A, 2006, 103(40):14895-900.
16	KesavardhanaS, Kanneganti TD. Targeting apoptosis inhibition to activate antitumor immunity[J]. Trends Immunol, 2019, 40(12):1073-1075.
17	Xia S, Wu J, Zhou W, et al. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells[J]. Cell Death Dis, 2021, 12(6):570.
18	VékonyN, WolS, BoisselJ, et al. Human cationic amino acid transporterh CAT-3 is preferentially expressed in peripheral tissues[J]. Biochemistry, 2001, 40, 12387-12394.
19	Nicholson B, Sawamura T, Masaki T, et al. Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines[J]. J Biol Chem, 1998, 273(24):14663-14666.
20	Nicholson B, Sawamura T, Masaki T, et al.Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines[J]. J Biol Chem, 1998, 273(24):14663-14666.
21	Yan L, He J, Liao X, etal. A comprehensive analysis of the diagnostic and prognostic value associated with the SLC7A family members in breast cancer[J]. Gland Surg, 2022, 11(2):389-411.
22	Sourbron J, Jansen K, Mei D, et al. SLC7A3: in silico prediction of a potential new cause of childhood epilepsy[J]. Neuropediatrics, 2022, 53(1):46-51.
23	He L, Xu Y, Lin J, et al. Increased SLC7A3 expression inhibits tumor cell proliferation and predicts a favorable prognosis in breast cancer[J]. Recent Pat Anticancer Drug Discov, 2024, Jan 8. doi: 10.2174/0115748928279007231130070056. Online ahead of print.
24	Sperandeo MP, Borsani G, Incerti B, et al. The gene encoding a cationic amino acid transporter (SLC7A4) maps to the region deleted in the velocardiofacial syndrome[J]. Genomics, 1998, 49(2):230-236.
25	Wolf S, Janzen A, Vékony N, et al. Expression of solute carrier7A4 (SLC7A4) in the plasma membrane is not sufficient to mediate amino acid transport activity[J]. Biochem J, 2002, 364(Pt3):767-775.
26	Gong W, Chen Y, Zhang Y. Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer[J]. Transl Cancer Res, 2021, 10(2):602-612.
27	Yan L, He J, Liao Xet al. A comprehensive analysis of the diagnostic and prognostic value associated with the SLC7A family members in breast cancer[J]. Gland Surg, 2022, 11(2):389-411.
28	Yang R, Wang Z, Li J, et al. The identification of the metabolism subtypes of skin cutaneous melanoma associated with the tumor microenvironment and the immunotherapy[J]. Front Cell Dev Biol, 2021, 9:707677.
29	Fan A, Zhang Y, Cheng J, et al. A novel prognostic model for prostate cancer based on androgen biosynthetic and catabolic pathways[J]. Front Oncol, 2022, 12:950094.
30	Nachef M, Ali AK, Almutairi SM, et al. Targeting SLC1A5 and SLC3A2/SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment[J]. Front Immunol, 2021, 12:624324.
31	Sato K, Miyamoto M, Takano M, et al. Significant relationship between the LAT1 expression pattern and che- moresistance in ovarian clear cell carcinoma[J]. Virchows Arch, 2019, 474:701-710.
32	Hisada T, Kondo N, Wanifuchi-Endo Y, et al. Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer[J]. Sci Rep, 2022, 12(1):16515.
33	Li Y, Wang W, Wu X, et al.SLC7A5 serves as a prognostic factor of breast cancer and promotes cell proliferation through activating AKT/mTORC1 signaling pathway[J]. Ann Transl Med, 2021, 9(10):892.
34	Li J, Qiang J, Chen SF, et al.The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma[J]. Tumor Biol, 2013, 34(5):2977-2981.
35	Quan L, Ohgaki R, Hara S, et al. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation[J]. J Exp Clin Cancer Res, 2020, 39(1):266.
36	Martinez RS, Salji MJ, Rushworth L, et al. SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer[J]. Cancer Res, 2021, 81(13):3664-3678.
37	Rii J, Sakamoto S, Mizokami A, et al. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity[J]. Cancer Sci, 2024 Jan 7. doi: 10.1111/cas.16062. Online ahead of print.
38	Morio H, Reien Y, Hirayama Y, et al. Protein kinase C activation upregulates human L-type amino acid transporter 2 function[J]. J Physiol Sci, 2021,71(1):11.
39	Chen X, Wang Z, Zhao X, et al. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1[J]. Oncogene, 2022, 41(17):2492-2504.
40	Milewski K, Bogacińska-Karaś M, Fręśko I, et al. Ammonia reduces intracellular asymmetric dimethylarginine in cultured astrocytes stimulating its y+LAT2 carrier-mediated loss[J]. Int J Mol Sci, 2017, 18(11):2308.
41	Closs EI, Ostad MA, Simon A, et al. Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina[J]. Biochem Biophys Res Commun, 2012, 423(2):218-223.
42	吕泊宁,宋红权,焦晓辉.泛癌中SLC7A7表达的预后意义及其与免疫微环境的关系[J].黑龙江医学, 2021, 45(15):1573-1578.
43	Fan S, Meng D, Xu T, et al. Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma[J]. Med Oncol, 2013, 30(1):384.
44	Dai W, Feng J, Hu X, et al. SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer[J]. Cancer Cell Int, 2021, 21(1):106.
45	Morio H, Reien Y, Hirayama Y, et al. Protein kinase C activation upregulates human L-type amino acid transporter 2 function[J]. J Physiol Sci, 2021, 71(1):11.
46	Rodriguez CF, Escudero-Bravo P, Díaz L, et al. Structural basis for substrate specificity of heteromeric transporters of neutral amino acids[J]. Proc Natl Acad Sci U S A, 2021, 118(49):e2113573118.
47	Tina E, Prosén S, Lennholm S, et al. Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma[J]. Br J Dermatol, 2019, 180(1):130-140.
48	El Ansari R, Alfarsi L, Craze ML, et al. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer[J]. Breast Cancer Res Treat, 2020, 181(1):1-12.
49	Meng F, Wang L, Gao G, et al. Identification and verification of microRNA signature and key genes in the development of osteosarcoma with lung metastasis[J]. Medicine (Baltimore), 2022, 101(49):e32258.
50	Baba H, Kanda M, Sawaki K, et al. SLC7A9 as a potential biomarker for lymph node metastasis of esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2022, 9(4):2699-2709.
51	Lee B, Lee SY, Han DH, et al. Interpretation of SLC3A1 and SLC7A9 variants in cystinuria patients: The significance of the PM3 criterion and protein stability[J]. Urolithiasis, 2023, 51(1):94.
52	Zhan R, Ge Y, Liu Y, et al. Genetic and clinical analysis of Chinese pediatric patients with cystinuria[J]. Urolithiasis, 2022, 51(1):20.
53	Villar-Quiles RN, Catervi F, Cabet E, et al.ASC-1 is a cell cycle regulator associated with severe and mild forms of myopathy[J]. Ann Neurol, 2020, 87(2):217-232.
54	Ussar S, Lee KY, Dankel SN, et al. ASC-1, PAT2, and P2RX5 are cell surface markers for white, beige, and brown adipocytes[J]. Sci Transl Med, 2014, 6(247):247ra103.
55	Jersin RÅ, Tallapragada DSP, Madsen A, et al. Role of the neutral amino acid transporter SLC7A10 in adipocyte lipid storage, obesity, and insulin resistance[J]. Diabetes, 2021, 70(3):680-695.
56	Muir A, Danai LV, Gui DY, et al. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition[J]. Elife, 2017, 6:e27713.
57	Shen L, Zhang J, Zheng Z, et al. PHGDH inhibits ferroptosis and promotes malignant progression by upregulating SLC7A11 in bladder cancer[J]. Int J Biol Sci, 2022, 18(14):5459-5474.
58	Zhang L, Liu W, Liu F, et al. IMCA induces ferroptosis mediated by SLC7A11 through the AMPK/mTOR pathway in colorectal cancer[J]. Oxid Med Cell Longev, 2020, 2020:1675613.
59	Zeng C, Lin J, Zhang K, et al. SHARPIN promotes cell proliferation of cholangiocarcinoma and inhibits ferroptosis via p53/SLC7A11/GPX4 signaling[J]. Cancer Sci, 2022, 113(11):3766-3775.

基因	编码蛋白	表达	相关疾病
SLC7A1	CAT-1	除肝脏、泪腺外的其他组织	卵巢癌^[6]、肝细胞癌^[7]、甲状腺激素释放异常^[9]、肝母细胞瘤^[51]
SLC7A2	CAT-1 （A or B）	CAT-2A：肝脏、骨骼肌、胰腺、CAT-2B：在多种细胞类型中可诱导	非小细胞癌^[11]、肺炎^[12]、乳腺癌^[13]、肝细胞癌^[52]
SLC7A3	CAT-3	胸腺、卵巢、睾丸、大脑（神经元）	乳腺癌^[17]、甲状腺癌^[17]、癫痫^[18]
SLC7A4	CAT-4	大脑、睾丸、胎盘	卵巢癌^[21]、乳腺癌^[22]、黑色素瘤^[23]、前列腺癌^[53]
SLC7A5	LAT1	大脑、卵巢、睾丸、胎盘、脾脏、结肠、血脑屏障	卵巢癌^[25]、乳腺癌^[27]、肝癌^[28]、前列腺癌^[30]
SLC7A6	y+LAT 2	大脑、小肠、睾丸、腮腺、心脏、肾脏、肺、胸腺	肝细胞癌^[32]、高血氨症^[33]、心血管疾病^[34]
SLC7A7	y+LAT 1	小肠、肾脏、脾脏、白细胞、胎盘、肺（基底外侧）	肾上腺皮质癌^[35]、肾嫌色细胞癌^[35]、脑胶质瘤^[35]、肝癌^[35][35]、胰腺癌^[35]、胸腺癌^[35]、葡萄膜黑色瘤^[35]、皮肤黑色素瘤^[35]、胶质母细胞瘤^[36]
SLC7A8	LAT 2	小肠、肾脏、肺、心脏、脾脏、肝脏、大脑、胎盘、前列腺、卵巢、胎儿肝脏、睾丸、骨骼肌	基底细胞癌^[40][40]、乳腺癌^[41]、骨肉瘤^[42]
SLC7A9	b0,AT	肾脏、小肠、肝脏、胎盘	食管鳞状细胞癌^[43]、胱氨酸尿症^[44]
SLC7A10	Asc-1	大脑、中枢神经系统、肺、小肠、心脏、胎盘、骨骼肌、肾脏	成纤维细胞细胞周期调节^[46]、胰岛素抵抗^[47][48]
SLC7A11	xCT	巨噬细胞、大脑、视网膜色素细胞、肝脏、肾脏	膀胱癌^[50]、结直肠癌^[54]、胆管癌^[55]
SLC7A13	AGT-1	近端小管、远曲小管	/

基因	编码蛋白	表达	相关疾病
SLC7A1	CAT-1	除肝脏、泪腺外的其他组织	卵巢癌^[6]、肝细胞癌^[7]、甲状腺激素释放异常^[9]、肝母细胞瘤^[51]
SLC7A2	CAT-1 （A or B）	CAT-2A：肝脏、骨骼肌、胰腺、CAT-2B：在多种细胞类型中可诱导	非小细胞癌^[11]、肺炎^[12]、乳腺癌^[13]、肝细胞癌^[52]
SLC7A3	CAT-3	胸腺、卵巢、睾丸、大脑（神经元）	乳腺癌^[17]、甲状腺癌^[17]、癫痫^[18]
SLC7A4	CAT-4	大脑、睾丸、胎盘	卵巢癌^[21]、乳腺癌^[22]、黑色素瘤^[23]、前列腺癌^[53]
SLC7A5	LAT1	大脑、卵巢、睾丸、胎盘、脾脏、结肠、血脑屏障	卵巢癌^[25]、乳腺癌^[27]、肝癌^[28]、前列腺癌^[30]
SLC7A6	y+LAT 2	大脑、小肠、睾丸、腮腺、心脏、肾脏、肺、胸腺	肝细胞癌^[32]、高血氨症^[33]、心血管疾病^[34]
SLC7A7	y+LAT 1	小肠、肾脏、脾脏、白细胞、胎盘、肺（基底外侧）	肾上腺皮质癌^[35]、肾嫌色细胞癌^[35]、脑胶质瘤^[35]、肝癌^[35][35]、胰腺癌^[35]、胸腺癌^[35]、葡萄膜黑色瘤^[35]、皮肤黑色素瘤^[35]、胶质母细胞瘤^[36]
SLC7A8	LAT 2	小肠、肾脏、肺、心脏、脾脏、肝脏、大脑、胎盘、前列腺、卵巢、胎儿肝脏、睾丸、骨骼肌	基底细胞癌^[40][40]、乳腺癌^[41]、骨肉瘤^[42]
SLC7A9	b0,AT	肾脏、小肠、肝脏、胎盘	食管鳞状细胞癌^[43]、胱氨酸尿症^[44]
SLC7A10	Asc-1	大脑、中枢神经系统、肺、小肠、心脏、胎盘、骨骼肌、肾脏	成纤维细胞细胞周期调节^[46]、胰岛素抵抗^[47][48]
SLC7A11	xCT	巨噬细胞、大脑、视网膜色素细胞、肝脏、肾脏	膀胱癌^[50]、结直肠癌^[54]、胆管癌^[55]
SLC7A13	AGT-1	近端小管、远曲小管	/

家族	成员	结构域	转运氨基酸	功能
CAT	SLC7A1、SCL7A2、SLC7A3、SLC7A4、SLC7A14	2A0303	碱性氨基酸	参与一氧化氮的合成^[59]
LAT	SLC7A5、SLC7A6、SLC7A7、SLC7A8、SLC7A9、SLC7A10、SLC7A11、SLC7A12、SLC7A13	2A0308、2A0308 super family	支链氨基酸、芳香族氨基酸、中性氨基酸和必需氨基酸	为细胞快速增殖提供必需氨基酸^[31]

家族	成员	结构域	转运氨基酸	功能
CAT	SLC7A1、SCL7A2、SLC7A3、SLC7A4、SLC7A14	2A0303	碱性氨基酸	参与一氧化氮的合成^[59]
LAT	SLC7A5、SLC7A6、SLC7A7、SLC7A8、SLC7A9、SLC7A10、SLC7A11、SLC7A12、SLC7A13	2A0308、2A0308 super family	支链氨基酸、芳香族氨基酸、中性氨基酸和必需氨基酸	为细胞快速增殖提供必需氨基酸^[31]

[1]	Breast Disease Branch of Guangdong Medical Association (Youth Committee of Breast Disease Branch of Guangdong Medical Association);, Breast Cancer Study Group Along the Yangtze River (YBCSG);, Breast Disease Branch of Chongqing Medical Association;, Breast Cancer Prevention and Treatment Committee of Guangdong Preventive Medicine Association. Experts consensus on platinum-based neoadjuvant therapy for triple negative breast cancer (2023 version) [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(01): 1-10.
[2]	Dan Wang, Jian Zhu, Jun Wang, Changrui Liu, Dongliang Zhai, Yixin Liu, Yuanyuan Liu, Shanshan Ming, Qingqing He. Clinical application of intraoperative radiotherapy in breast-conserving surgery for early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(01): 11-17.
[3]	Yurou Xue, Jie Kong, Longyu Zhu, Huina Han, Jun Zhang, Zhikun Liu. Local treatment for isolated locoregional recurrence in breast cancer patients after mastectomy [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(01): 18-24.
[4]	Yuanxin Zhang, Junhua Huang, Jiaqiang Dan, Cheng Xiao, Junyan Li. NR4A2 is an early molecular marker predicting recurrence and metastasis of breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(01): 31-39.
[5]	Min Cai, Shaozhong Wei, Yijing Luo. Application of different anti-reflux digestive tract reconstruction techniques in patients with gastric cancer after proximal gastrectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 137-140.
[6]	Lin Zhang, Ting Li. Study on the expression of CRIP1 in gastric cancer and its relationship with clinicopathological index and prognosis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 171-175.
[7]	Jisiguleng Wu, Wa Hasigao. Expression of mir-98-5p and ALKBH1 in hilar cholangiocarcinoma and their relationship with clinicopathological features [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 184-187.
[8]	Hailong Shen, Jianguo Zhang, Yiyang Shao, Xiaochao Zhou, Chunlai Guo, Zhe Kuang. Clinical study of TME+LLND after neoadjuvant therapy for locally advanced low rectal cancer with lateral lymphoid short diameter <10 mm [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 192-195.
[9]	Bo Wu, Yongming Zheng, Shiqiang Du. Value analysis of SPECT/CT and serum sTg levels in predicting the risk of lymph node metastasis in patients treated with ¹³¹I after thyroid cancer surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 212-216.
[10]	Jing Chen, Xiaoling Wang, Kang An. Related factors and treatment progress of postoperative peritoneal metastasis in elderly patients with advanced gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 225-228.
[11]	Mingda Tan, Jun Yan, Shixiang Guo. Analysis of complications after duodenum, common bile duct and sphincter of Oddi-preserving pancreatic head total resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(02): 145-150.
[12]	Chan Zhang, Yao Lyu, Xiaoyan Zhang, Mingqing Zhang. Comparison of analgesic effects of regional nerve blocks at different time points in open hepatectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(02): 189-194.
[13]	Chuanhai Zhang, Yi Zhou, Yifan Wang, Jinliang Ma. Laparoscopic anatomical hepatectomy via cystic plate approach using "peritoneal reflection" combined with ICG fluorescence navigation (video attached) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 62-67.
[14]	Yuanyuan Chen, Hongli Yan. Genetic blockade in hereditary colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(01): 1-5.
[15]	Yiyi Cai, Guochun Lou, Dong Xu, Ying Yuan. Optimization of screening and follow-up strategies for hereditary colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(01): 14-20.

Please choose a citation manager

Content to export